Returning guest, Dr. Steve Marcus, CEO of Cantex Pharmaceuticals, a clinical-stage pharmaceutical company focused on developing transformative therapies for cancer and other life-threatening medical conditions for which new treatments are urgently needed discusses Azeliragon and the launch of investigator-led clinical studies focusing on a combination with radiosurgery in patients with brain metastases, front-line treatment for glioblastoma, metastatic pancreatic cancer and treatment of patients hospitalized with COVID-19 and pneumonia to prevent acute kidney injury. #CantexPharmaceuticals STEPHEN G. MARCUS, M.D., CHIEF EXECUTIVE OFFICER    Stephen G. Marcus, M.D. is a physician who has focused his professional career on the development of new treatments for cancer and other life-threatening and disabling diseases. Born and educated in New York City, Dr. Marcus received his medical degree from New York Medical College. After an internal medicine residency at Lenox Hill Hospital in New York, and oncology specialty training at the University of California in San Francisco, Dr. Marcus spent several years practicing emergency and critical care medicine and medical oncology.       In 1985, Dr. Marcus entered the biotechnology industry where he has been directly responsible or played a critical role in the development of a number of important new medications. Dr. Marcus was the leader of the team of scientists and physicians who developed Betaseron as the first effective treatment of multiple sclerosis. This revolutionized the treatment of multiple sclerosis and was the forerunner of the many drugs for multiple sclerosis that are available today. Dr. Marcus played a key role in the development of fludarabine for a chronic lymphocytic leukemia, and served as the leader of multinational teams of researchers developing new treatments of cancer, multiple sclerosis, as well as other life-threatening or disabling conditions.

Dr. Michael R. Jaff, Vice President and Chief Medical Officer, Peripheral Interventions at Boston Scientific and Dr. Peter Monteleone, MD, FACC, FSCAI an interventional cardiologist and vascular medicine physician at Ascension Texas Cardiovascular in Austin, Texas and principal investigator of the REAL-PE study talk about the study results and the potential for real-world data to improve patient care in pulmonary embolism treatment and beyond. #REALPEStudy #EKOS #Truveta Michael R. Jaff, DO is the Vice President and Chief Medical Officer, Peripheral Interventions at Boston Scientific. A former professor of medicine at Harvard Medical School, Dr. Jaff was the President of Newton-Wellesley Hospital from October 2016-December 2019. Prior to that, Dr. Jaff was the inaugural Paul and Phyllis Fireman Endowed Chair of Vascular Medicine and Medical Director of the Fireman Vascular Center at the Massachusetts General Hospital. He is an expert in all aspects of vascular medicine, including peripheral artery disease, venous thromboembolic disease, aneurysmal diseases, and all diagnostic strategies in vascular medicine. He is the founder of VasCore, the Vascular Ultrasound Core Laboratory, the largest of its’ kind in the United States. VasCore has participated in trial design and independent analysis of vascular laboratory images for over 200 prospective multicenter peripheral vascular device and pharmaceutical trials across 66 countries. Dr. Jaff has published extensively in the field of Vascular Medicine with over 325 peer reviewed publications and 10 textbooks, is the Past-President of the Society for Vascular Medicine and Biology and was the first physician to have received the designation as Master of the Society for Vascular Medicine. He is a Fellow of the American College of Physicians, American College of Cardiology, the American Heart Association, and the Society for Cardiovascular Angiography and Intervention, and is a registered physician in vascular interpretation (RPVI).

David Berman, Head of Research and Development at Immunocore discusses the 3-year overall survival data from the  KIMMTRAK Phase 3 trial that  was presented at the European Society of Medical Oncology (ESMO) 2023  for their FDA approved treatment for uveal melanoma, a very deadly type of cancer in the eye. It was the first-ever approved treatment in the space. #Immunocore Dr. David Berman is Head of Research and Development. Over his career, David has worked on multiple immuno-oncology (IO) programs at all stages of development including leadership roles in developing four approved biologics. Most recently, David was Senior Vice President and Head of the AstraZeneca IO Franchise, responsible for the strategy and execution of the Company’s late stage IO program.   Prior to that, he was Head of the early stage oncology program at MedImmune. David has also held senior development roles at Bristol-Myers Squibb including as Head of the Immuno-oncology exploratory development team and global clinical lead for the first approved IO checkpoint inhibitor and one of the first monoclonal antibodies approved for myeloma. Beginning in academia and throughout his industry career, David has led efforts to understand the mechanism of action and predict benefit from IO therapies. David received a Bachelor’s of Science from the Massachusetts Institute of Technology and MD and PhD from the University of Texas Southwestern Medical School. He trained in pathology at the National Cancer Institute followed by a fellowship at the Johns Hopkins Hospital.

Joan Lau, Ph.D., MBA, CEO of Spirovant Sciences discusses cystic fibrosis (CF) and how the standard of care right now addresses but does not correct the underlying cause of the disease. She talks about what needs to be done, and how her organization is working to revolutionize treatment for people living with CF by directly targeting and correcting the underlying cause of the disease. #SpirovantSciences Joan Lau is Chief Executive Officer of Philadelphia-based biotech Spirovant Sciences. She co-founded the company (then called Talee Bio), envisioning the potential for gene therapy for patients with inherited respiratory diseases. Under her leadership, Spirovant gained the support of the Cystic Fibrosis Foundation and was honored as PACT Healthcare Startup of the Year. Spirovant was acquired twice in 2019, once as part of a $3 billion transaction with Sumitomo Pharma. Dr. Lau co-founded and is partner with Militia Hill Ventures, a firm focused on forming and growing life sciences companies. Previously she held roles as COO of Immunome (IMNM); President and CEO of Azelon Pharmaceuticals; and President and CEO of Locus Pharmaceuticals, a computational chemistry discovery company. VELEXBRU ® was discovered & developed at Locus under her leadership. Dr. Lau began her career at Merck Research Laboratories. Dr. Lau has been recognized for her entrepreneurial accomplishments and leadership in the biotechnology industry and within the Philadelphia and social justice non-profit communities. She serves on the board for the Philadelphia Orchestra & Kimmel Center; the Penn School of Social Policy and Practice; Brandywine Realty Trust; and Rockwell Medical, Inc. She is an Adjunct Professor at Penn in the Wharton Healthcare Management Program. Previously she served as national board chair, Human Rights Campaign Foundation (DC). She was selected as the 2020 EY Entrepreneur of the Year, Philadelphia Region; a 2020 Woman of Distinction by the Philadelphia Business Journal; and the 2021 Iris Newman Award recipient from the Alliance for Women Entrepreneurs. Dr. Lau earned an MBA from the Wharton School of Business and a BSE in Bioengineering, both at the University of Pennsylvania; and a PhD in Neuroscience from the University of Cincinnati College of Medicine.

Dr. Lishan Aklog, MD, Chairman and CEO of Lucid Diagnostics, a commercial-stage cancer prevention diagnostics company, discusses the company’s EsoGuard ® Esophageal DNA Test and EsoCheck ® Esophageal Cell Collection Device, the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer, targeting the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. #EsoGuard Lishan Aklog, M.D. has served as Lucid’s Chairman and Chief Executive Officer since its IPO in October 2021 and previously served as its Executive Chairman since its inception in 2018. Dr. Aklog also co-founded and has served as Chairman and Chief Executive Officer of Lucid’s parent company, PAVmed Inc (Nasdaq: PAVM) since its inception in 2014, and as Executive Chairman of PAVmed’s other major subsidiary, digital health company Veris Health Inc., since its inception.​ Dr. Aklog has been active in the life sciences for several decades, including as an executive, entrepreneur, public company director, technological innovator, corporate advisor, and, previously, as an innovator in cardiac surgery at leading academic medical centers, including Harvard Medical School and Mount Sinai School of Medicine. He is a medical technology industry leader who serves on the Board of Directors of the Advanced Medical Technology Association (AdvaMed), the world’s leading medical technology trade association, and was recognized as one the Top Healthcare Technology CEOs of 2021 by Healthcare Technology Report.​ Dr. Aklog began his career as a medical technology entrepreneur and executive in 2007, as co-founding Partner of both Pavilion Holdings Group (PHG), a medical device holding company, and Pavilion Medical Innovations (PMI), its venture-backed medical device incubator. He co-founded Vortex Medical Inc., a PHG portfolio company which developed and commercialized the revolutionary AngioVac ® system and served as its Chairman and Chief Technology Officer from its inception until its acquisition by AngioDynamics Inc. Dr. Aklog is an inventor on 35 issued patents and dozens of patent applications, including the patents of the AngioVac system and the majority of the PAVmed’s products. His patents have been honored by the Boston Museum of Science and the Boston Patent Lawyers Association.​ Dr. Aklog has served in various other capacities across the life sciences industry including on the Board of Directors and the Audit Committee of Contrafect Inc. (Nasdaq: CFRX), a biopharmaceutical company, and previously on the Board of Directors and as Chair of the Audit Committee of Viveon Health Acquisition Corp. (NYSE: VHAQ), a healthcare special purpose acquisition corporation (SPAC). Over his career, Dr. Aklog has served as a consultant to and on the Scientific Advisory Boards of numerous leading medical device companies, including Medtronic Inc., St. Jude Medical Inc., now Abbott Laboratories, Guidant Cardiac Surgery, now, Getinge AB, and Cardiovations, then, a division of Johnson & Johnson, as well as numerous early-stage medical technology companies. ​

Dr. Mary McGowan, MD, Chief Medical Officer at the Family Heart Foundation, discusses a recent study that revealed concerning findings showing the diagnosis and treatment of a rare genetic disorder, homozygous familial hypercholesterolemia (HoFH), is dangerously underdiagnosed and undertreated. Results published in the Journal of the American Heart Association (JAHA) by the Family Heart Foundation found that diagnosis of HoFH, a condition which can lead to severely elevated low-density lipoprotein cholesterol (LDL-C), often does not occur until a heart attack or other cardiac event. #FamilyHeartFoundation Mary P. McGowan, MD Chief Medical Officer, Family Heart Foundation Dr. Mary McGowan received her medical degree from the University of Massachusetts. She remained at the University of Massachusetts Medical Center for both internship and residency. She completed her fellowship at Johns Hopkins Hospital. Dr. McGowan is the Co-Director of the Lipid Clinic at Dartmouth Hitchcock Heart and Vascular Center. She is the author of numerous articles and five books. She has been the principal investigator on over 30 national and international clinical trials and has lectured widely in the United States, Canada, Europe and Asia on cholesterol metabolism. Dr. McGowan serves on the alumni board at the University of Massachusetts Medical Center and the National Lipid Association Foundation Board. She has previously served on the National Lipid Association Board of Directors, the NH Affiliate of the American Heart Association Board and was the first Chief Medical Officer of the Familial Hypercholesterolemia Foundation.

Jeremiah Robison, Founder and CEO of CIONIC discusses the company's success with the FDA-Cleared Cionic Neural Sleeve, the first bionic clothing to combine sensing, analysis, and augmentation to help individuals with neurological conditions like multiple sclerosis, stroke, and cerebral palsy live more freely and independently. CIONIC is now licensed to ship to over 90% of US states (and growing), with over 400 prescribing institutions and 200,000 hours of customer use. #neurotech #multiplesclerosis #cerebralpalsy Jeremiah Robison is the Founder and CEO of CIONIC, an innovative company that builds lightweight and durable bionic clothing driven by powerful algorithms that adapt in real-time to each individual's mobility needs. He started the company in 2018 after his daughter was diagnosed with cerebral palsy and he was frustrated at the lack of effective technology available to help improve her mobility. Four years later, CIONIC introduced the breakthrough, FDA-cleared Cionic Neural Sleeve, the first product to combine sensing, analysis and augmentation into a wearable garment. Prior to CIONIC, Jeremiah spent twenty years at the intersection of data, algorithms, and the human body, driving innovation in sensing and machine learning at Apple, Openwave Systems, Slide, and Jawbone. Jeremiah has a BS and MS in Computer Science from Stanford University.

Dr. Charles Vega, MD, Family Medicine Specialist and Director of Irvine’s Program in Medical Education for the Latino Community discusses Boehringer Ingelheim and Lilly’s launch of It Takes 2, a new health initiative to elevate the importance of complete testing and early diagnosis of kidney disease, particularly among those who have type 2 diabetes or high blood pressure and are at greater risk for it. Boehringer Ingelheim and Lilly partnered with musical artist Rob Base to release a remix of his ‘80’s hit song "It Takes Two" that underscores how It Takes 2 people – a patient and a healthcare professional – and two tests– eGFR and UACR – to detect kidney disease. View the “It Takes 2 – The Remix” music videos and access educational resources on the initiative’s website at CKDtesting.com. #chronickidneydisease #kidneydisease #CKD Charles Vega, M.D., is a family medicine specialist and Director of UC Irvine’s Program in Medical Education for the Latino Community. He has spent his entire 27-year medical career at UCI’s Family Health Center, the largest safety-net clinic in Orange County, where he teaches medical students and residents. His academic interests are focused on access to quality, compassionate medical care for underserved populations, and the development of training programs to promote this vision of healthcare. He is a member of various associations, including American Academy of Family Practice, California Academy of Family Physicians, California Medical Association and National Hispanic Medical Association.

Dr. Michael Boland, MD, PhD, Site Director, Mass Eye and Ear, Lexington, Medical Director, Practice Innovation for Ophthalmology, Massachusetts Eye and Ear and Associate Professor of Ophthalmology, Harvard Medical School discusses presentations from the 2023 American Academy of Ophthalmology annual meeting regarding AI and glaucoma. #AAO2023 #AI #glaucoma Dr. Boland is a member of the Glaucoma Service at Mass Eye and Ear and the Site Director at Mass Eye and Ear, Lexington. He has completed sub-specialty training in the medical and surgical management of glaucoma and is available for consultations for both glaucoma and cataracts. In addition to his clinical practice, Dr. Boland serves as Medical Director of Practice Innovation for Ophthalmology where he provides expert guidance on technology-based innovations that improve the quality of patient care and increase practice efficiency and safety. He has held national leadership positions related to information systems in ophthalmology and is uniquely qualified to embrace new innovations and accelerate the use of technology, including telemedicine.

Dr. Terence Rooney, Vice President, Rheumatology, Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development shares new data that was presented from the Phase 2a IRIS proof-of-concept study, demonstrating the efficacy and safety of nipocalimab in the first-ever clinical study of an FcRn inhibitor in adults living with moderate to severe rheumatoid arthritis, and supporting its progression into an anti-TNF combination study. These data were presented at the 2023 American College of Rheumatology (ACR) Convergence. #ACR23 #Immunology #Rheumatology Terence Rooney, M.D., is Vice President, Rheumatology, Immunology Disease Area Leader for the Immunology Therapeutic Area at Janssen Research & Development, LLC. In this role, he is responsible for driving scientific leadership in the rheumatology disease area, overseeing innovative compounds across multiple phases of development. In his prior role at Janssen as Vice President, Immunology Clinical Development, Terence led the Late Development Clinical organization, overseeing all late-stage Immunology clinical trials. Under his leadership, the team delivered many important milestones, and evolved to meet the present and future needs of our growing and complex Immunology portfolio more sustainably. Prior to his time at Janssen, Terence held positions of increasing responsibility in translational/early and late clinical development at Roche and Eli Lilly, respectively. Terence received his medical degrees from the Royal College of Surgeons in Ireland. During 10 years of academic clinical practice at teaching hospitals in Dublin, he completed postgraduate training in Rheumatology and Internal Medicine. His clinical/translational research fields of interest included rheumatoid arthritis biomarkers for the evolving targeted therapy era, in which he acquired a doctoral degree. He completed a post-fellowship attachment at the University of California San Francisco Division of Rheumatology before transitioning to work full time in pharmaceutical research and development. Terence is based at the Spring House, Pennsylvania campus, and lives with his family in Gladwyne, Pennsylvania. Follow Terence on LinkedIn here.

Dr. Arlene Siefker-Radtke, Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center in Houston, TX discusses her presentation at ESMO 2023, abstracts #2362MO and #2359O on Erdafitinib (erda) from the Phase 3 THOR study. For more information visit: https://www.annalsofoncology.org/article/S0923-7534(23)04015-2/fulltext and https://www.nejm.org/doi/full/10.1056/NEJMoa2308849 #ESMO2023 Arlene O Siefker-Radtke, MD is a Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX. She is a graduate of The Johns Hopkins University School of Medicine and has been in practice for more than 20 years.

Dr. Nicolas Girard, Professor of Respiratory Medicine at Versailles Saint Quentin University and head of the Curie-Montsouris Thorax Institute discusses his presentation at ESMO 2023 - Presidential Symposium / Abstract #LBA5 - Amivantamab plus carboplatin/pemetrexed vs carboplatin/pemetrexed as first line treatment in EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): primary results from PAPILLON, a randomized phase 3 global study. #ESMO2023 #LBA5 Nicolas Girard is a pneumologist specializing in thoracic oncology, for the treatment of patients with lung cancer or rare thoracic cancers. He is experienced in the treatment of thymic tumors—thymomas and thymic carcinomas—as part of his work in the RYTHMIC network. He is domain leader for rare thoracic cancers for the European Reference Network EURACAN. Nicolas Girard is involved in several clinical and translational research projects aiming at improving the treatment of these cancers. He is the Président of the International Thymic Malignancy Interest Group. He is Professor of Respiratory Medicine at Versailles Saint Quentin University. He is the Head of the Curie-Montsouris Thorax Institute.

Dr. Kim Chi, Senior Research Scientist, Vancouver Prostate Centre discusses his presentation at ESMO 2023, abstract #LBA85 - Niraparib (NIRA) with abiraterone acetate plus prednisone (AAP) as first-line (1L) therapy in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations: Three-year update and final analysis (FA) of MAGNITUDE. #ESMO2023 Senior Research Scientist, Vancouver Prostate Centre Chief Medical Officer & Vice President, BC Cancer Medical Oncologist, BC Cancer – Vancouver Professor, Department of Medicine, UBC Dr. Chi is a medical oncologist with BC Cancer who, at a relatively early stage in his career, has received national and international recognition for his contributions to prostate cancer research. Dr. Chi's research is focused in the area of genitourinary cancers with a special interest in prostate cancer and investigational new drugs. This includes phase I, II and III clinical trials, therapeutic use of antisense oligonucleotides and mechanisms of treatment resistance. He has had peer reviewed grant funding for the conduct of early phase clinical trials and associated correlative studies from the Canada Institutes of Health Research (CIHR), Canadian Cancer Society Research Institute, The U.S. Department of Defense, the Prostate Cancer Foundation (USA), Movember and Prostate Cancer Canada. Nationally and internationally he has led a number of multi-centre Phase I, II and III clinical trials including cooperative group studies and investigator sponsored studies with agents sourced from the US National Cancer Institute's Cancer Therapy Evaluation Program (NCI CTEP) and industry collaborators. He has led the phase I through III development of two novel compounds (OGX-011 and OGX-427), which came from academic preclinical development at the Vancouver Prostate Centre. He has also contributed to clinical trials that established new standard of care for patients with advanced prostate cancer (docetaxel, abiraterone acetate, enzalutamide). On July 1, 2019, Dr. Chi was appointed Vice President and Chief Medical Officer, BC Cancer. Prior to this, he was the medical director of the Clinical Trials Unit at the BC Cancer Agency – Vancouver Centre. He was appointed Chair of the Genitourinary Systemic Group at the BC Cancer Agency in 2003. This group is responsible for developing systemic treatment management guidelines for patients with genitourinary cancers in the province of British Columbia (available at www.bccancer.bc.ca) and securing access to new therapies through the province’s health care system. Under his guidance as medical director of the Clinical Trials Unit at the BC Cancer Agency – Vancouver Centre (which provides access for patients to the latest in investigational new drugs through phase I, II and III clinical studies), the not-for-profit Clinical Trials Unit almost doubled patient accrual to trials, becoming a self-sustaining growth operation. Dr. Chi is Professor with the Department of Medicine at the University of British Columbia. He is also the Co-Chair of the Genitourinary Disease Site for the Canadian Cancer Trials Group (CCTG) and the Canadian Uro-Oncology Group, which is responsible for developing the genitourinary cancer trials undertaken by investigators at a national cooperative group level. In addition, he is an Executive Committee Member and Past-Chair of the Investigational New Drug Site for the CCTG, which is responsible for developing early phase I/II trials across the CCTG disease sites.

Wensheng Fan, CEO and co-founder of Spectral AI, a company that is using artificial intelligence to revolutionize diagnostics and wound care, discusses the recently awarded Biomedical Advanced Research and Development Authority (BARDA) Project BioShield Contract. This contract is for the advanced development of the DeepView  System, the Company’s AI-driven burn wound imaging technology, to be used at emergency departments, trauma centers and burn centers, for both routine burn care and as a medical countermeasure for use in burn mass casualty incidents (BMCI). DeepView ® records imaging data of the wound and uses an AI algorithm to predict wound healing patterns based on a large proprietary clinical database. #SpectralAI ​#AI #WoundHealing Wensheng Fan CEO and Co-Founder of Spectral AI, Inc., an award-winning, publicly traded predictive analytics company that develops proprietary artificial intelligence (AI) algorithms and optical technology for fast, accurate treatment decisions in wound care. Since launching the company in 2009, Wensheng has led engineering of the AI platform and DeepView ® product line, an FDA Breakthrough Designated medical imaging system, from concept and prototype to an FDA 501(K) cleared product, securing more than $150M in public and private funding to date. Wensheng has 20 years of experience in pioneering market-disruptive natural speech recognition, real-time imaging systems, and AI driven predictive medical solutions. Before Spectral AI, Wensheng played pivotal roles in product development for start-up and large, international companies including Sensata Technologies, Navini Networks (acquired by Cisco), Precision Drilling Corporation (acquired by Weatherford), and Phillips Speech Processing. Mr. Fan received his B.S.E.E. degree from Tsinghua University in Beijing, China and M.S.E.E. degree from Northeastern University in Boston.

Voyce is a technology-driven company dedicated to breaking down language barriers in healthcare. CEO of Voyce, Andrew Royce, discusses how the company delivers simple, seamless, and secure on-demand medical interpretation in more than 240 languages and dialects, 24/7. The app is designed to work with smartphones, tablets, laptops, desktops, iOS, Android, Telephonic and APIs. It is easily integrated into virtual care platforms and EMRs, such as EPIC, Teladoc, and Zoom. #languageinterpreation #healthequity #healthcareenterprise Andrew Royce, CEO of Voyce Serving as a volunteer resettling Syrian refugees in Canada, Andrew Royce became acutely aware of the need for on-demand, medically qualified language interpreters that could reliably and confidentially support healthcare patients who don’t speak English. His passion for this service has been the catalyst behind Voyce. By putting the dignity of non-English speakers first and working to solve the pain points of those accessing language services through innovative new technologies, Royce has led the now global company to great commercial success and outstanding user satisfaction. Voyce now supports about 5,000,000 conversations per year and created about 1,500 sustainable work opportunities for language interpreters in over 70 countries.

Trial investigator Brian Slomovitz, MD, Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center, discusses results from the global, randomized, open-label Phase 3 innovaTV 301 trial, which showed treatment with tisotumab vedotin demonstrated statistically significant and clinically meaningful overall survival, progression-free survival, and objective response in recurrent or metastatic cervical cancer patients with disease progression on or after first-line therapy, compared with chemotherapy. innovaTV301 A specialist in clinical trial development, robotic surgery, sentinel lymph node evaluation, and immunotherapy, Dr. Brian Slomovitz is Director of Gynecologic Oncology and Co-Chair of the Cancer Research Committee at Mount Sinai Medical Center in Miami Beach, Florida. He is also a Professor of Obstetrics and Gynecology at Florida International University. Dr. Slomovitz is a member of the Board of Directors at the GOG Foundation and the Uterine Cancer Lead for GOG Partners. He is also the national or global principal investigator on a number of GOG Partners, NCI, and Alliance Foundation clinical trials. He authored more than 100 peer-reviewed articles and lectured extensively. In addition, Dr. Slomovitz has been recognized as a Top Doctor by Castle Connolly Medical for the past several years. Dr. Slomovitz graduated from Rutgers University – New Jersey Medical School, and completed his residency at New York Presbyterian – Cornell Medical Center in 2002. At MD Anderson Cancer Center, he completed a fellowship in gynecologic oncology in 2006. He is board certified in both obstetrics and gynecology and gynecologic oncology.

Jeff Hackman, CEO of Comera Life Sciences, discusses how the company uses its proprietary SQore™ viscosity reduction platform to transform intravenous (IV) biologics into subcutaneous (SQ) versions that patients can self-administer in a single dose. High viscosity is a significant hurdle to formulating subcutaneous biologics and Comera’s addition of excipients, such as caffeine, interrupts intermolecular interactions to reduce viscosity of high concentration monoclonal antibody formulations. These self-administered SQ biologics have significant potential benefits over IV infusion for patients and payers. Comera is leveraging its SQore platform in multiple ongoing collaborations with biopharma companies to enhance both commercial biologics and those in early development stages. For more information on Comera Life Sciences, visit https://comeralifesciences.com. #biologics #formulation #drugdelivery Jeffrey S. Hackman is Chairman and Chief Executive Officer of Comera Life Sciences. Prior to joining Comera, Jeff was President of US Operations for EUSA, a global pharmaceutical company focused on oncology and rare diseases. Previously, he had been acting CEO of Novelion Therapeutics, where he transformed the company to profitability. He joined Novelion from Shire Inc., where he had been Senior VP and Head of US Internal Medicine / Oncology Franchise. Previously, he established the North American oncology commercial division for Baxalta, following several years leading US commercial operations for Sigma Tau. He has also held senior roles in several other pharmaceutical companies.

Dr. ​Jeffrey Popma​, MD, Vice President and Chief Medical Officer for Coronary, Renal Denervation, and Structural Heart at Medtronic discusses Medtronic’s recent CE Mark approval for the Evolut™ FX TAVI System and the increased need for solutions for patients with symptomatic severe aortic stenosis. #Medtronics #Hearthealth Jeffrey Popma, MD, is the Vice President and Chief Medical Officer for Coronary, Renal Denervation, and Structural Heart at Medtronic, a position that he has held since June 2020. Dr. Popma received his BA in Economics from Stanford University and received an MD with the highest distinction from Indiana University School of Medicine. He completed his internship, residency, chief residency in Internal Medicine, and Cardiovascular Fellowship at the University of Texas Southwestern Medical Center in Dallas, TX. He also completed an Interventional Cardiology fellowship at the University of Michigan in Ann Arbor, MI. He has been former interventional faculty at Medstar Washington Hospital Center in Washington, DC and the Brigham and Women’s Hospital in Boston, MA. Dr. Popma was most recently the Director of Interventional Cardiology Clinical Services at the Beth Israel Deaconess Medical Center in Boston, MA, and a Professor of Medicine at Harvard Medical School. Dr. Popma was also the director of the BIDMC Imaging Core Laboratory which completed over 500 studies in coronary, renal denervation, peripheral vascular disease, and structural heart. Dr. Popma has been the national or local investigator for a broad array of new technology, including bare metal stents, drug eluting stents, distal protection devices, total occlusion devices, carotid and peripheral revascularization procedures, and transcatheter valve therapy. Dr. Popma is the Past President of the Society for Cardiac Angiography and Intervention, and a Past Co-Chair of the Interventional Council of the American College of Cardiology. Dr. Popma has served on the editorial boards of numerous publications. He has published over 500 peer-reviewed manuscripts.

Dr. Joe Kimura, Chief Medical Officer, discusses how Somatus deployed a robust transitions-of-care (TOC) service to help their patients safely transition from acute inpatient care to home. Somatus provides TOC services to CKD3/4/5 and ESKD patients and has found patients in the program are 49% less likely to be re-admitted to the hospital compared to usual care.    #Health #Healthcare #Kidneycare Dr. Kimura joins Somatus from Atrius Health, a 650+ physician Boston-based independent multispecialty practice serving 700,000 patients across Eastern MA. Transitioning after almost two decades from a Boston-based multispecialty group practice known as a national leader in value based accountable care, in his role as Somatus’ Chief Medical Officer, he is laser-focused on the provision of world class kidney care and works to help reduce the burden of end-stage-kidney disease in this country. Dr. Kimura works closely with our clinical care team leadership at Somatus to advance our clinical operations and improve patient outcomes as we continue to scale significantly across multiple markets and partner with providers and healthcare delivery systems to drive more healthy days at home. He is board certified in Internal Medicine and Clinical Informatics and has been a national advocate for the practical applications of clinical informatics and healthcare analytics to improve care delivery. Dr. Kimura is a graduate of Stanford University, Washington University School of Medicine, and Harvard School of Public Health. He completed his residency training in primary care internal medicine at UCSF, his health services research fellowship at HMS, and the MIT Sloan Executive Program in Management, Innovation, and Technology in 2015. He is a faculty member in the Department of Population Medicine at Harvard Medical School.

Dr. Thomas Carroll, Director at Brigham and Women's Voice Program and the Medical Director of Otolaryngology Clinics at Brigham and Women's Hospital discusses his presentations from the 2023 American Academy of Head and Neck Surgery conference, hot topics, and current challenges in the field of ENT. #AAOHNS #Brigham&Womens Dr. Thomas Carroll is the Director at Brigham and Women's Voice Program and the Medical Director of Otolaryngology Clinics at Brigham and Women's Hospital. He is the President of the New England Chapter of the Voice Foundation. He is also the Assistant Professor in Otology and Laryngology at Harvard Medical School. He received his medical degree from Wright State University School of Medicine and completed a residency in otolaryngology at the University of Colorado Denver and Health Sciences Center. He then completed a fellowship in laryngology and care of the professional voice at the University of Pittsburgh Medical Center Voice Center.